Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18432558 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4EALDH1A1GLA | |
| SCHEMBL22561885 | 0.67 | GABRA1 (0.38) | MEN1KMT2ACYP2D6 | |
| SCHEMBL20009414 | 0.65 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22562067 | 0.62 | CYP2D6 (0.40) | CYP2D6 | |
| SCHEMBL24080244 | 0.59 | MEN1 (0.42) | MEN1KMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL17059003 | 0.59 | MEN1 (0.59) | MEN1KMT2AKDM4EALDH1A1GLA | |
| SCHEMBL23654930 | 0.58 | MEN1 (0.36) | MEN1KMT2AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL21507836 | 0.57 | MEN1 (0.35) | MEN1KMT2AKDM4EALDH1A1CYP3A4 | |
| SCHEMBL11024692 | 0.57 | NFE2L2 (0.54) | MEN1KMT2AKDM4EALDH1A1TSHR | |
| SCHEMBL11024683 | 0.57 | NFE2L2 (0.54) | MEN1KMT2AKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |